CLINICAL TRIALS PROFILE FOR DEPODUR

All Clinical Trials for DEPODUR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00335517 ↗	Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients	Completed	EKR Therapeutics, Inc	N/A	2006-06-01	The purpose of the study is to help determine the appropriate dose of DepoDur for use in spinal surgery. The study will also assess the safety of this drug in this patient population.
NCT00335517 ↗	Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients	Completed	University of Rochester	N/A	2006-06-01	The purpose of the study is to help determine the appropriate dose of DepoDur for use in spinal surgery. The study will also assess the safety of this drug in this patient population.
NCT00456638 ↗	Clinical Study of Depodur Efficacy in Decreasing Post Operative Pain After Off Pump Coronary Artery Bypass Grafting (OP-CABG)	Withdrawn	Drexel University College of Medicine	N/A	2008-04-01	The purpose of this study is to determine whether epidural Depodur alleviates the pain of OP-CABG surgery. This includes pain associated with sternotomy, retraction, dissection and other tissue insults, as well as the induced inflammatory system and effects from prolonged ventilation in the ICU setting.
NCT00708318 ↗	Study Evaluating Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Normal Healthy Subjects	Completed	YM BioSciences	Phase 1	2001-10-01	This was a pilot, phase I, two-period, fasting, bioavailability, safety,and pharmacokinetic study evaluating single dose of i.v. fentanyl (200 µg) and single doses of 2 mL or 3 mL inhaled AeroLEF (500 µg/mL) delivered by nebulization with the AeroEclipse BAN device administered in normal healthy non-smoking subjects.

Clinical Trial Conditions for DEPODUR

Condition Name

Condition Name for DEPODUR
Intervention	Trials
Morphine Adverse Reaction	1
Pain	1
Pain Management	1
Pain, Postoperative	1

Condition MeSH

Condition MeSH for DEPODUR
Intervention	Trials
Pain, Postoperative	3
Agnosia	1
Muscle Spasticity	1
Cerebral Palsy	1

Clinical Trial Locations for DEPODUR

Trials by Country

Trials by Country for DEPODUR
Location	Trials
United States	8
Canada	1

Trials by US State

Trials by US State for DEPODUR
Location	Trials
New York	2
Missouri	1
North Carolina	1
Kentucky	1
Colorado	1

Clinical Trial Progress for DEPODUR

Clinical Trial Phase

Clinical Trial Phase for DEPODUR
Clinical Trial Phase	Trials
Phase 4	4
Phase 1	2
N/A	5

Clinical Trial Status

Clinical Trial Status for DEPODUR
Clinical Trial Phase	Trials
Completed	5
Terminated	4
Withdrawn	1

Clinical Trial Sponsors for DEPODUR

Sponsor Name

Sponsor Name for DEPODUR
Sponsor	Trials
EKR Therapeutics, Inc	4
University of Louisville	1
Wake Forest University	1

Sponsor Type

Sponsor Type for DEPODUR
Sponsor	Trials
Other	9
Industry	6

Depodur (morphine sulfate) Clinical Trials Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is Depodur and what is its current clinical position?

Depodur is a durable-release epidural morphine sulfate formulation intended for post-operative analgesia. It is administered into the epidural space (commonly in the setting of major surgery), aiming to extend pain control relative to immediate-release opioids.

No complete, verifiable clinical-trials update (new phase progress, primary endpoint results, or recent regulatory filings) is provided in the information available in this chat, so a complete and accurate “clinical trials update” cannot be produced to the standards required.

What is the competitive and commercial landscape for durable-release epidural morphine?

Depodur’s commercial positioning depends on a few structural factors: (1) utilization of epidural analgesia pathways, (2) hospital procurement preferences for post-operative pain control, and (3) the availability of competing long-acting regional or systemic opioid options.

Key commercial vectors

• Procedure mix: spine and orthopedic volumes drive addressable use for epidural analgesia products.
• Protocol adoption: standardized pathways for post-operative pain management influence use frequency.
• Budget impact: hospital formularies weigh total cost of care, length of stay, rescue analgesic use, and adverse event burden.

Competitive set (high level)

The primary competitive pressure comes from:

• Other long-acting opioids (systemic) with reduced dosing frequency
• Other regional analgesia approaches (e.g., local anesthetic techniques that reduce opioid exposure)
• Dose-and-duration alternatives within hospital formularies

A complete market analysis that includes competitors’ product-specific performance, share, and pricing for Depodur requires product-level data that is not present in this chat.

What is the addressable market for Depodur?

A credible market projection requires a base epidemiology/procedure model (major surgeries likely to use epidural analgesia), conversion to treated patients, and then product penetration.

In this chat, there is no dataset for:

• volume of eligible procedures
• current Depodur utilization rate
• regional adoption rates
• pricing and reimbursement inputs

Without those inputs, a complete and accurate market projection cannot be produced.

Market projection: base, bull, and bear scenarios

A three-scenario projection requires definable assumptions tied to real-world utilization, pricing trends, and competitive dynamics. None of those inputs are available here in verifiable form. Therefore, no numeric projection is produced.

---

Key Takeaways

• Depodur is a durable-release epidural morphine sulfate product used for post-operative analgesia.
• A complete and accurate clinical trials update and market projection cannot be generated from the information available in this chat.
• Producing investable market forecasts requires procedure volumes, current penetration, and price/reimbursement trend inputs that are not present.

---

FAQs

1) Is Depodur a generic product or a branded therapy?

Depodur is a branded durable-release epidural morphine sulfate product.

2) What setting uses Depodur most often?

It is used for post-operative pain control via epidural administration, typically in major surgical settings.

3) What endpoint matters most for Depodur’s clinical value?

In practice, durability of analgesia (time to rescue analgesia and pain control over the intended dosing window) and safety (notably opioid-related adverse events) are key.

4) What drives Depodur demand commercially?

Hospital adoption of epidural analgesia protocols and case volume for procedures where epidural pain management is standard.

5) What would most affect a Depodur market forecast?

Real-world penetration of durable-release epidural opioid pathways, reimbursement, pricing, and substitution by alternative analgesia strategies.

---

References

[1] No sources were cited because no verifiable clinical or market data for Depodur was provided in the conversation.